Clinical meanings of midkine expression in cerebrospinal fluid of patients with gliomas

LUO Si-liang; XIA Zhi-bo

doi:10.13798/j.issn.1009-153X.2017.06.017

Abstract：Objective To investigate the expression of midkine (MK) in cerebrospinal fluid (CSF) and its relationship with clinicopathological features in patients with gliomas.Methods The level of MK in CSF were determined by enzyme linked immunosorbent assay in 25 patients with gliomas including WHO grades Ⅰ ～ Ⅱ gliomas (15 cases) and WHO grades Ⅲ ～Ⅳ gliomas (10 cases),23 patients with benign tumors and 18 patients with other lesions including communicating hydrocephalus (10 cases) and trigeminal neuralgia (8 cases).The MK expression were detected by immunohistochemical technique in 25 glioma patients after operative.Results The level of MK expression in CSF with gliomas was significantly higher in the patients with gliomas than those in the patients with benign tumors and non-neoplasms (P＜0.001).The level [(7.02±4.62) ng/ml] of MK in CSF was significantly higher in the patients with WHO grades Ⅲ ～Ⅳ gliomas than that [(3.20±1.84) ng/ml] in the patients with WHO grades Ⅰ ～ Ⅱ gliomas (P＜0.05).The level of MK expression in CSF was positively related with that in the tumorous tissues in the patients with gliomas (r=0.751,P＜0.001).The level of MK expression in CSF significantly declined from 7 to 14 days after the resection of tumors compared to that before the operation in the patients with gliomas (P＜0.05).Conclusion It is suggested that the level of MK in CSF may be helpful to the diagnosis of human gliomas.